Over the last decades, the advances in the treatment of patients with ST-segment–elevation myocardial infarction (STEMI) have resulted in a reduced mortality. However, the incidence of rehospitalization for heart failure (HF) as a consequence of the development of adverse left ventricular (LV) remodeling remains unacceptably high and the long-term mortality is equally worrisome [1]. Infarct size has long been known to be an independent predictor of LV remodeling and adverse outcomes after myocardial infarction (MI).